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Recognition of multifocal vasculopathy due to varicella-zos-
ter virus (VZV) is often problematic. We describe a human
immunodeficiency virus–infected patient who had progres-
sive central nervous system disease for 13 months. Both VZV
DNA and antibody were detected in cerebrospinal fluid (CSF)
specimens; serial polymerase chain reaction analyses con-
firmed the diagnosis and guided the duration of therapy.
Reduced ratios of VZV antibody in serum to that in CSF
were also demonstrated.
Multifocal vasculopathy due to varicella-zoster virus (VZV) is
often difficult to recognize because neurological symptoms and
signs can assume many forms and because brain imaging stud-
ies reveal multifocal lesions similar to those seen with cerebral
emboli, metastases, lymphoma, and toxoplasmosis. We describe
an HIV-infected patient with progressive CNS disease who was
determined to have multifocal vasculopathy due to VZV.
Case report. A 28-year-old man who was infected with
HIV and hepatitis C virus was hospitalized for progressive diz-
ziness of 3 months’ duration and recent-onset left-side weak-
ness. Nine months earlier, his CD4 cell count was 13 cells/mL
and his HIV load in serum was 92,029 copies/mL. When diz-
ziness and vertigo developed, the patient underwent neurolog-
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ical examination and CT of brain, the findings of which were
normal. Two weeks before admission, the patient began re-
ceiving antiretroviral therapy with lamivudine (150 mg b.i.d.),
zidovudine (300 mg b.i.d.), nelfinavir (1250 mg b.i.d.), and
trimethoprim-sulfamethoxazole (160 mg/800 mg 3 times per
week). His medical history was otherwise unremarkable; he
never developed cutaneous herpes zoster. On admission, he was
afebrile. Neurological examination revealed left-side mydriasis
without ptosis or anhidrosis, a left-side hemiparesis and ho-
monymous hemianopia, and neglect to the left. Laboratory
studies revealed a hemoglobin level of 9.1 g/dL, a WBC count
of 2550 cells/mL, and a normal platelet count. C-reactive protein
and serum electrolyte levels were normal, and the findings of
chest radiography and of liver and renal function studies were
normal.
CT of brain revealed contrast-enhancing lesions in the right
occipitotemporal and parieto-occipital cortices (figure 1A).
MRI of the brain corroborated the vascular distribution of the
lesions and also revealed prominent subcortical edema (figure
1B, 1C); a small signal of uncertain significance, which was
possibly ischemic, was also seen close to the right lateral ven-
tricle (figure 1B). The findings of magnetic resonance angiog-
raphy were normal.
Analysis of CSF specimens obtained from the patient re-
vealed 11 WBCs/mm3 (95% mononuclear), a protein level of
135 mg/dL, and a normal glucose level. The results of Venereal
Disease Research Laboratory testing of CSF specimens were
negative; culture of CSF specimens revealed no bacteria, in-
cluding mycobacteria; and no cryptococcal antigen or Toxo-
plasma-specific IgG was detected. Serum was also negative for
IgG antibody to Toxoplasma. PCR analysis of CSF specimens
with primers specific for bacterial 16S RNA [1] and Toxo-
plasma species, cytomegalovirus, Epstein-Barr virus, herpes
simplex virus types I and II, and JC virus DNA were negative.
However, PCR with primers specific for VZV glycoprotein I
gene (open-reading frame 67) amplified VZV DNA. PCR was
done with use of TaqMan chemistry and the following se-
quences: 5′-ACAGCTTGTCTTTATTGGAGAGCAA-3′ as the
forward primer, 5′-GCCACCGTATCCGCGTATA-3′ as the re-
verse primer, and 5′-(FAM)-ACCTACCGGGACAAACTATA-
GCGGAACACTG-(TAMRA)-3′ as the probe. Furthermore,
VZV antibody analysis indicated a decrease in the ratio of
VZV-specific IgG in serum to that in CSF to 0.89, compared
with ratios of 39 for albumin and 44 for total IgG, which is
consistent with intrathecal synthesis of VZV-specific IgG [2].
Because encephalitis due to Toxoplasma species could not be
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Figure 1. A, Contrast-enhanced CT of the brain of a patient with varicella-zoster virus multifocal vasculopathy showing contrast-enhancing lesions
(arrows) in right occipitotemporal and parieto-occipital cortices. B, MRI of brain showing 2 lesions (arrows) in right occipitotemporal and parieto-
occipital cortices. A small contrast-enhancing lesion, which is possibly ischemic, is visible close to right lateral ventricle (arrowhead). C, T2-weighted
MRI showing subcortical edema (arrow) extending into optic radiation and a small area of increased signal adjacent to internal capsule and frontal
horn (arrowhead). D, T2-weighted MRI from 5 months after treatment revealing residual right posterior hemispheric infarcts (arrows) and a small CSF-
filled infarct close to lateral ventricle (arrowhead).
excluded initially, the patient was treated empirically with sul-
fadiazine (1500 mg q.i.d.) and pyrimethamine (75 mg q.d.).
On detection of both VZV-specific DNA and antibody in CSF
specimens, the diagnosis of VZV multifocal vasculopathy was
confirmed, and the patient was treated with intravenous acy-
clovir (10 mg/kg t.i.d.) for 24 days. Treatment efficacy was
monitored by serial real-time PCR analysis of CSF specimens.
A 4-log reduction in the number of VZV DNA copies (from
104 copies/mL [day 0] to copies/mL [day 14] and to15 10
!101 copies/mL [day 21]) was observed when all CSF samples
were analyzed in parallel. After receiving intravenous acyclovir
treatment for 21 days, the patient had no neurological symp-
toms, and the results of PCR of CSF specimens for VZV DNA
were negative. Acyclovir therapy was discontinued 3 days later,
and a 4-week course of oral valacyclovir (2000 mg t.i.d.) was
begun. Five months after the initiation of valacyclovir therapy,
the findings of a neurological examination were normal, and
MRI performed at this time showed residual cortical infarcts
(figure 1D).
Discussion. In the past decade, the protean clinical features
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of VZV multifocal vasculopathy have been well characterized
[3]. Most, but not all, patients are immunocompromised, usu-
ally because of AIDS, and disease is often protracted and may
progress without rash [4–7]. Symptoms and signs include com-
binations of headache, fever, mental status changes, seizures,
and focal deficit. Brain imaging studies reveal both large and
small infarcts of both cortical and subcortical gray and white
matter; infarcts are usually ischemic [8, 9] but may also be
hemorrhagic [10]. In this regard, the diagnosis of VZV vas-
culopathy might have been recognized earlier for our patient
had contrast-enhanced MRI initially been performed instead
of CT. Testing of CSF specimens usually yields nonspecific re-
sults, showing increased WBC count (predominantly mono-
nuclear cells), with elevated protein and normal glucose levels.
Although diagnosis can be difficult to make when the patient
lacks a history of rash, it is important to recognize that rash
is often absent from patients with CNS disease caused by VZV.
A retrospective analysis of 34 HIV-infected patients with ce-
rebral VZV infection showed that 17.6% of the patients never
developed rash [11]. Nevertheless, the multifocal changes de-
tected on brain imaging studies should mandate the need for
virological analysis to confirm that VZV is the cause of disease.
In the aforementioned clinical setting, the detection of VZV
DNA and/or antibody to VZV in CSF specimens verifies the
diagnosis of VZV-induced multifocal vasculopathy [12]. Similar
virological analyses have shown that VZV also causes acute,
chronic, and recurrent myelitis [13], as well as acute, chronic,
and recurrent neuropathies [14], often without rash, including
chronic radicular pain without rash (the so-called “zoster sine
herpete”) [15].
In our patient, both VZV DNA and antibody to VZV were
detected in CSF specimens. Also, serial PCR analyses to monitor
VZV DNA in CSF over time not only confirmed the diagnosis,
but they also guided the duration of therapy, which led to a
beneficial outcome for our patient. As described elsewhere in
a study of 3 children with VZV-associated cerebral vasculitis
[16], decreased ratios of antibody to VZV in serum to that in
CSF were demonstrated, providing definitive evidence for the
viral etiology of disease in our patient. Detection of reduced
ratios of antibody to VZV in serum/CSF has been critical for
the diagnosis of VZV autonomic neuropathy [17] and VZV
myelitis [18, 19]. Previous antibody studies of cases of VZV
vasculopathy revealed high titers of antibody to VZV in CSF
specimens, which emphasizes the diagnostic value of detecting
VZV antibody in CSF, even when viral DNA is not present
[19]. However, the ability to demonstrate reduced ratios of
antibody in serum to that in CSF in our patient was the linchpin
in our diagnosis that VZV caused the multifocal vasculopathy.
No controlled studies have addressed the duration of anti-
viral treatment necessary to treat VZV multifocal vasculopathy.
The duration of treatment for HIV-infected patients has ranged
from 7 to 60 days [11]. Monitoring of VZV DNA in CSF and
of intrathecal antibody production should help to establish
guidelines for the duration of antiviral treatment to protect
patients from recurrent disease. It is unlikely that antiretroviral
therapy contributed essentially to the recovery in our patient,
because antiretroviral therapy was initiated only 2 weeks before
acyclovir therapy.
Finally, clinicians must be alert to the clinical manifestations
of VZV multifocal vasculopathy, the characteristic abnormal-
ities visible on MRIs, and the importance of confirming the
diagnosis by virological analysis of CSF specimens. Although
multiple areas of the brain are affected, VZV-induced multifocal
vasculopathy is not a primary encephalitis (i.e., parenchymal
infection) but rather a productive VZV infection, mostly or
exclusively restricted to cerebral arteries [6, 9, 20–23]. This fact
emphasizes the need for rapid diagnosis and antiviral treatment
to eradicate virus in arteries and to prevent further stroke. The
failure of clinicians to recognize the entity of VZV-induced
multifocal vasculopathy was evident in a recent review in which
the causes of focal neurological disease in patients with AIDS
were listed as Toxoplasma gondii, progressive multifocal leu-
koencephalopathy, cytomegalovirus, and Epstein-Barr virus–
related CNS lymphoma, without any mention of VZV multi-
focal vasculopathy [24].
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